Anita J Brogan (A J Brogan)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 8

Top Topics

Multidrug Resistant

Men Who Have Sex With Men

Top Venues

PharmacoEconomics

This page only lists publications with an associated author ORCID identifier.

Publications

Anita J Brogan, Ashley E Davis, Claire E Mellott, Jeremy Fraysse, Aimee A Metzner, Alan K Oglesby
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. PharmacoEconomics 42 (4) (2024)
Anita J Brogan, Ashley E Davis, Claire E Mellott, Jeremy Fraysse, Aimee A Metzner, Alan K Oglesby
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. PharmacoEconomics 42 (4) (2024)
Anita J Brogan, Ashley E Davis, Claire E Mellott, Jeremy Fraysse, Aimee A Metzner, Alan K Oglesby
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. PharmacoEconomics 42 (4) (2024)
Anita J Brogan, Ashley E Davis, Claire E Mellott, Jeremy Fraysse, Aimee A Metzner, Alan K Oglesby
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. PharmacoEconomics 42 (4) (2024)
Anita J Brogan, Ashley E Davis, Claire E Mellott, Jeremy Fraysse, Aimee A Metzner, Alan K Oglesby
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. PharmacoEconomics (2024)
Anita J Brogan, Sandra E Talbird, Ashley E Davis, Elizabeth M La, Princy N Kumar
The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States. PharmacoEconomics 39 (4) (2021)
Anita J Brogan, S E Talbird, A E Davis, L Wild, D Flanagan
Is increased screening and early antiretroviral treatment for HIV-1 worth the investment? An analysis of the public health and economic impact of improvement in the UK. HIV medicine 20 (10) (2019)
Anita J Brogan, Ashley E Davis, Bridgett Goodwin
Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States. PloS one 13 (8) (2018)